It is important to emphasise that if you (or a family member) are being treated with a Napp product and you have a question or concern about your treatment, it is recommended that you speak to your Healthcare Professional in the first instance, as they will be best-placed to assist you.
Reporting of Side Effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects you can help provide more information on the safety of this medicine.
Medicines showing a black triangle symbol (▼) are subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See yellowcard.mhra.gov.uk for how to report side effects.
The medicines are listed by alphabetical order of the active ingredient. Patient Information Leaflets (PILs) are the most suitable information for patients and public, however you may also review the Summary of Product Characteristics (SmPC) and/or regulatory Assessment Report (AR) if you wish, although both of the document types are primarily intended for Healthcare Professionals.
Due to the UK’s recent exit from the European Union, some medicines now have separate information available for Northern Ireland (NI) and Great Britain (GB), whereas the information for some products is still applicable across the United Kingdom (UK). Please ensure you select the link corresponding to the part of the UK where you are resident.
Medicines marked with an exclamation mark (!) are in the process of being discontinued and may have limited availability. Please speak to your Healthcare Professional if you have any concerns.
UK-INV-2100223
Date of Prep: Aug 2021
